Cytosorbents (CTSO) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Cytosorbents (CTSO) over the last 9 years, with Q3 2025 value amounting to $1.61.
- Cytosorbents' Debt to Equity rose 5376.32% to $1.61 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.61, marking a year-over-year increase of 5376.32%. This contributed to the annual value of $1.26 for FY2024, which is 48674.72% up from last year.
- As of Q3 2025, Cytosorbents' Debt to Equity stood at $1.61, which was up 5376.32% from $1.24 recorded in Q2 2025.
- Over the past 5 years, Cytosorbents' Debt to Equity peaked at $1.61 during Q3 2025, and registered a low of $0.14 during Q4 2022.
- In the last 4 years, Cytosorbents' Debt to Equity had a median value of $0.78 in 2024 and averaged $0.73.
- Its Debt to Equity has fluctuated over the past 5 years, first skyrocketed by 5194.35% in 2023, then soared by 48674.72% in 2024.
- Cytosorbents' Debt to Equity (Quarter) stood at $0.14 in 2022, then soared by 51.94% to $0.21 in 2023, then soared by 486.75% to $1.26 in 2024, then grew by 28.16% to $1.61 in 2025.
- Its Debt to Equity was $1.61 in Q3 2025, compared to $1.24 in Q2 2025 and $0.98 in Q1 2025.